FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment
RegulatoryapprovedPrecivityAD2Positive
AI Analysis
Summary
FDA has cleared C2N Diagnostics' PrecivityAD2 blood test, a precision diagnostic for Alzheimer's disease that can be used in patients as young as 40. This milestone represents the culmination of nearly two decades of ADDF investment in advancing scalable blood-based diagnostics for early Alzheimer's detection.
Outcome Details
FDA clearance of PrecivityAD2 blood test for patients as young as 40
Importance:8/10
Sentiment:
0.85
FDA approvaldiagnostic testblood testAlzheimer's diseaseprecision medicineearly detection
Read the original article
Published by PR Newswire Biotech on August 20, 2026 9:01 PM